ordastobart + pembrolizumab

**ordastobart + pembrolizumab** (INBRX-106 + Keytruda) is an investigational combination immunotherapy under development for the treatment of various solid tumors, including head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). Ordastobart (INBRX-106) is a humanized, hexavalent single-domain antibody (sdAb)-based agonist that targets OX40 (CD134), a costimulatory receptor expressed on T cells, designed to enhance T-cell activation and proliferation. Pembrolizumab (Keytruda) is an approved monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2 to release PD-1 pathway-mediated inhibition of the immune response. By combining OX40 agonism with PD-1 pathway blockade, the regimen aims to synergistically boost the immune system's anti-tumor response. The combination is being evaluated in Phase 2/3 clinical trials as a first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.

Other names

INBRX-106 + KeytrudaINBRX-106 + pembrolizumabKeytruda + INBRX-106ordastobart + Keytrudapembrolizumab + INBRX-106pembrolizumab + ordastobart